IMX-110, a water-soluble formulation composed of nanoparticles encapsulating a STAT3, NF-κB, poly-tyrosine kinase inhibitor (TKI), and doxorubicin is also under phase I and II clinical investigation for advanced solid tumors including, pancreatic cancer, breast cancer and ovarian cancer (NCT03382340). This evidence concerns the gene STAT3 and familial pancreatic carcinoma.